Dose-Reduced Apixaban for Thromboembolism in a Patient With Obesity on Cobicistat: A Case Report
- 26 October 2026
- journal article
- other
- Published by SAGE Publications in Journal of Pharmacy Practice
Abstract
Background/Objective: Current guidelines recommend a 50% dose reduction of apixaban for patients receiving strong CYP3A4/P-glycoprotein (P-gp) inhibitors regardless of body habitus. However, evidence supporting this dose adjustment in patients with severe obesity (BMI >40 kg/m 2 ) is limited. This report describes the use of dose-reduced apixaban for the treatment of venous thromboembolism in a patient with a BMI >50 kg/m 2 receiving a strong CYP3A4/P-gp inhibitor. Summary: A 38-year-old female with a BMI of 81.71 kg/m 2 and a history of HIV on a cobicistat-containing antiretroviral regimen was diagnosed with a left femoral deep vein thromboembolism. She was initially treated with warfarin and enoxaparin bridge therapy but was transitioned to apixaban prior to discharge. Apixaban was initiated at a 50% dose reduction due to the concomitant use of cobicistat, a strong CYP3A4/P-gp inhibitor. The patient successfully completed therapy without recurrence of thromboembolism or bleeding complications. Conclusion: This case demonstrates the successful use of dose-reduced apixaban in a patient with a BMI >50 kg/m 2 receiving a CYP3A4/P-gp inhibitor for the treatment of venous thromboembolism and adds to available literature on apixaban dosing in patients with obesity.Keywords
This publication has 11 references indexed in Scilit:
- Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism: Results of an Expert Consensus PanelThe American Journal of Medicine, 2023
- Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme ObesityAnnals of Pharmacotherapy, 2022
- Drug Interactions Affecting Oral Anticoagulant UseCirculation: Arrhythmia and Electrophysiology, 2022
- Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United StatesJournal of Thrombosis and Thrombolysis, 2022
- Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case ReportJournal of Pharmacy Practice, 2022
- Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of AnticoagulationJournal of Thrombosis and Haemostasis, 2021
- Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFYAdvances in Therapy, 2021
- American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary EmbolismBlood Advances, 2020
- Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reportsPharmacology Research & Perspectives, 2020
- Direct oral anticoagulants in extremely obese patients: OK to use?Research and Practice in Thrombosis and Haemostasis, 2018